BR0210239A - Uso de imunoglobinas policlonais e vacina - Google Patents
Uso de imunoglobinas policlonais e vacinaInfo
- Publication number
- BR0210239A BR0210239A BR0210239-0A BR0210239A BR0210239A BR 0210239 A BR0210239 A BR 0210239A BR 0210239 A BR0210239 A BR 0210239A BR 0210239 A BR0210239 A BR 0210239A
- Authority
- BR
- Brazil
- Prior art keywords
- polyclonal
- vaccine
- immunoglobins
- immunoglobulins
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"USO DE IMUNOGLOBULINAS POLICLONAIS E VACINA". A presente invenção refere-se ao uso de uma preparação de imunoglobulina policlonal para a fabricação de uma formulação de vacina, contendo anticorpos de diferentes especificidades, para a imunização de indivíduos da mesma espécie, dos quais derivam as imunoglobulinas. Essa preparação ativamente imunizante pode ser empregada por exemplo para a profilaxia ou para o tratamento de câncer, de doenças auto-imunes, alergias ou de predisposição a infecções virais, bacterianas ou fúngicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0086001A AT410637B (de) | 2001-06-01 | 2001-06-01 | Verwendung von polyklonalen immunglobulinen |
| PCT/AT2002/000088 WO2002096455A2 (de) | 2001-06-01 | 2002-03-19 | Verwendung von polyklonalen immunglobulinen als impfstoff |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210239A true BR0210239A (pt) | 2004-03-30 |
Family
ID=3682339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210239-0A BR0210239A (pt) | 2001-06-01 | 2002-03-19 | Uso de imunoglobinas policlonais e vacina |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040151717A1 (pt) |
| EP (1) | EP1399185A2 (pt) |
| JP (1) | JP2004532261A (pt) |
| CN (1) | CN1512895A (pt) |
| AT (1) | AT410637B (pt) |
| AU (1) | AU2002242447B2 (pt) |
| BR (1) | BR0210239A (pt) |
| CA (1) | CA2449026A1 (pt) |
| CZ (1) | CZ20033273A3 (pt) |
| HU (1) | HUP0400031A3 (pt) |
| IL (2) | IL158950A0 (pt) |
| MX (1) | MXPA03010829A (pt) |
| NO (1) | NO20035282D0 (pt) |
| PL (1) | PL367835A1 (pt) |
| SK (1) | SK14662003A3 (pt) |
| WO (1) | WO2002096455A2 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10127712A1 (de) * | 2001-06-07 | 2002-12-19 | Torsten Witte | Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis |
| WO2005023867A1 (en) * | 2003-09-08 | 2005-03-17 | Medical Research Council | Method for the treatment or prophylaxis of tuberculosis |
| CN106999588A (zh) * | 2014-12-03 | 2017-08-01 | 瑞士杰特贝林生物制品有限公司 | 具有增加的稳定性的包含免疫球蛋白的药物产品 |
| FR3072880A1 (fr) * | 2017-10-30 | 2019-05-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Formulation liposomale et son utilisation en therapie anti-tumorale |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3340487A1 (de) * | 1983-11-09 | 1985-05-15 | Sandoz-Patent-GmbH, 7850 Lörrach | Neue therapeutische verwendung |
| EP0438803B1 (en) * | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| JP2795289B2 (ja) * | 1990-09-04 | 1998-09-10 | 富士通株式会社 | 電子機器におけるプリント板ユニットの保持構造 |
| US5219578A (en) * | 1991-02-25 | 1993-06-15 | Innovet, Inc. | Composition and method for immunostimulation in mammals |
| WO1992015885A1 (en) * | 1991-03-11 | 1992-09-17 | Idec Pharmaceuticals Corporation | Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations |
| US5562902A (en) * | 1994-03-14 | 1996-10-08 | Arp Biomed, Inc. | Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin |
| TWI248819B (en) * | 1999-09-27 | 2006-02-11 | Arp Biomed Ltd | Pharmaceutical composition containing IVIG for use in treating lymphoma |
| AT409086B (de) * | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
| WO2001096392A2 (en) * | 2000-06-15 | 2001-12-20 | Millennium Pharmaceuticals, Inc. | 22109, a novel human thioredoxin family member and uses thereof |
| AT410636B (de) * | 2001-03-23 | 2003-06-25 | Igeneon Krebs Immuntherapie | Verfahren zur herstellung eines impfstoffes |
-
2001
- 2001-06-01 AT AT0086001A patent/AT410637B/de not_active IP Right Cessation
-
2002
- 2002-03-19 US US10/478,942 patent/US20040151717A1/en not_active Abandoned
- 2002-03-19 BR BR0210239-0A patent/BR0210239A/pt not_active Application Discontinuation
- 2002-03-19 EP EP02707990A patent/EP1399185A2/de not_active Withdrawn
- 2002-03-19 JP JP2002592964A patent/JP2004532261A/ja active Pending
- 2002-03-19 CA CA002449026A patent/CA2449026A1/en not_active Abandoned
- 2002-03-19 IL IL15895002A patent/IL158950A0/xx active IP Right Grant
- 2002-03-19 HU HU0400031A patent/HUP0400031A3/hu unknown
- 2002-03-19 SK SK1466-2003A patent/SK14662003A3/sk not_active Application Discontinuation
- 2002-03-19 CZ CZ20033273A patent/CZ20033273A3/cs unknown
- 2002-03-19 WO PCT/AT2002/000088 patent/WO2002096455A2/de active Application Filing
- 2002-03-19 CN CNA028111214A patent/CN1512895A/zh active Pending
- 2002-03-19 PL PL02367835A patent/PL367835A1/xx not_active Application Discontinuation
- 2002-03-19 MX MXPA03010829A patent/MXPA03010829A/es unknown
- 2002-03-19 AU AU2002242447A patent/AU2002242447B2/en not_active Ceased
-
2003
- 2003-11-19 IL IL158950A patent/IL158950A/en not_active IP Right Cessation
- 2003-11-27 NO NO20035282A patent/NO20035282D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03010829A (es) | 2004-02-17 |
| AT410637B (de) | 2003-06-25 |
| PL367835A1 (en) | 2005-03-07 |
| IL158950A (en) | 2008-04-13 |
| EP1399185A2 (de) | 2004-03-24 |
| HUP0400031A2 (hu) | 2004-04-28 |
| JP2004532261A (ja) | 2004-10-21 |
| WO2002096455A3 (de) | 2003-12-24 |
| AU2002242447B2 (en) | 2007-11-08 |
| HUP0400031A3 (en) | 2006-03-28 |
| US20040151717A1 (en) | 2004-08-05 |
| NO20035282L (no) | 2003-11-27 |
| CN1512895A (zh) | 2004-07-14 |
| NO20035282D0 (no) | 2003-11-27 |
| CA2449026A1 (en) | 2002-12-05 |
| ATA8602001A (de) | 2002-11-15 |
| WO2002096455A2 (de) | 2002-12-05 |
| CZ20033273A3 (en) | 2004-07-14 |
| SK14662003A3 (sk) | 2004-05-04 |
| IL158950A0 (en) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021222935A3 (en) | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof | |
| TR200200472T2 (tr) | Anti-Erb B2 antikorları ile tedavi için dozajlar | |
| BR0315157A (pt) | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste | |
| Crawley et al. | Porcine Ig isotypes: function and molecular characteristics | |
| CY1108578T1 (el) | Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων | |
| ATE208820T1 (de) | Humanisierte antikoerper | |
| IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
| AU2002302255A1 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
| ATE419872T1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
| BR0211296A (pt) | Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado | |
| EA202091690A1 (ru) | Иммуногенная композиция, содержащая стафилококковые антигены | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| DK1037650T3 (da) | Præparater til behandling af Staphylococcus aureus-infektioner | |
| Coelho et al. | Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing | |
| US10160802B2 (en) | Anti-malarial compositions | |
| WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
| WO2007084107A3 (en) | Monoclonal antibodies that neutralize anthrax protective antigen (pa) toxin | |
| CN105473613A (zh) | 产生中和金黄色葡萄球菌lukgh(lukab)毒素的高效抗体 | |
| BR0210239A (pt) | Uso de imunoglobinas policlonais e vacina | |
| HUP0400840A2 (hu) | Kis molekulatömegű hialuronsav immunogén készítményei, és eljárások A. csoportbeli és C. csoportbeli Streptococcusok által okozott fertőzések és betegségek megelőzéséhez, kezeléséhez és diagnózisához | |
| MX2020009851A (es) | Anticuerpos anti-pfrh5 y fragmentos de unión al antígeno de estos. | |
| BR112023000455A2 (pt) | Tratamento de doença inflamatória que usa anticorpos de fator antitecidual | |
| WO2021067633A3 (en) | Kir3dl3 is an inhibitory receptor of the immune system and uses thereof | |
| JP6498612B2 (ja) | 脱毛誘発物質を抗原とした抗体、組成物および製造方法 | |
| WO2005013898A3 (en) | Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |